Key statistics
On Friday, Biontech SE (22UA:FRA) closed at 99.85, -14.80% below its 52-week high of 117.20, set on Sep 17, 2024.
52-week range
Open | 101.00 |
---|---|
High | 102.30 |
Low | 99.40 |
Bid | 99.55 |
Offer | 101.60 |
Previous close | 98.60 |
Average volume | 96.85k |
---|---|
Shares outstanding | 237.77m |
Free float | 214.95m |
P/E (TTM) | -- |
Market cap | 26.70bn USD |
EPS (TTM) | -2.34 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 19:22 BST.
More ▼
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
- Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron KP.2 angepassten COVID-19-Impfstoff in der Europäischen Union
- EQS-News: MIG Capital portfolio company Inbolt raises €15 million in Series A to further develop AI-powered 3D vision in robots
- BioNTech veranstaltet am 1. Oktober 2024 „AI Day“ als eine Ausgabe der „Innovation Series“
- BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
- BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
- BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
- Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
- Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19 bei Personen im Alter von 18 bis 64 Jahren bekannt
More ▼